ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年04月28日 09時00分
Source:
Eisai
エーザイ、Institutional Investor誌の「The All-Japan Executive Team」において、「Most Honored Company」およびセクター第1位に選出
東京, 2020年04月28日 - (JCN Newswire) - エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、米国金融情報誌「Institutional Investor」がこのたび発表した「The All-Japan Executive Team」のBiotechnology & Pharmaceuticalsセクターにおいて、「Best CEOs」「Best CFOs」でそれぞれ第1位となり、「Most Honored Company」およびセクター総合第1位に選定されたことをお知らせします。
本調査は、世界的に著名な金融情報誌である「Institutional Investor」が、世界の機関投資家やアナリストの投票をもとに優れたIR活動を行う日本企業をセクターごとに選出するランキングです。2020年は、189の機関に所属する約350名の投資家・アナリストが投票を行いました。当社は、投資家説明会をはじめとする高質なIR活動や、ESGへの積極的な取り組みなどが高い評価を受けるとともに、CEO内藤 晴夫が、信頼性、コミュニケーションの質、リーダーシップで高く評価されました。
詳細は、「Institutional Investor」誌ホームページをご参照ください。（英語）www.institutionalinvestor.com/research/9955/the-all-japan-executive-team
当社は、患者様とそのご家族の喜怒哀楽を第一義に考え、そのベネフィット向上に貢献し、世界のヘルスケアの多様なニーズを充足することを企業理念に定めています。当社は、この理念の実現のため、株主・投資家の皆様の権利を尊重し、経営の公正性・透明性を確保し、企業価値向上の一助となるIR活動に取り組んでまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202019.html
概要：エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
Jul 18, 2026 00:24 JST
Hitachi and NVIDIA collaborate to advance HMAX and enable end-to-end autonomous operations through the integrated control of physical AI
Jul 17, 2026 23:35 JST
Toyota's First "BE creation" Spin-Off Begins Operations in Japan
Jul 17, 2026 23:00 JST
MHI Advances AI Infrastructure Commercialization with U.S. Deployment of 10MW-Class Chiller and MCP Development
Jul 17, 2026 22:47 JST
Noetra Launches Full-Scale R&D for Japan-Developed Multimodal Foundation Model
Jul 17, 2026 22:16 JST
Mitsubishi Motors Launches the Xforce HEV in Indonesia
Jul 17, 2026 21:47 JST
Fujitsu to explore physical AI development and implementation across industries with FANUC, Yaskawa Electric, and Kawasaki Heavy Industries integrating NVIDIA technology
Jul 17, 2026 21:05 JST
JCB Celebrates 30 Years of Trust, Honoring 70 Years of Japan-Philippines Friendship
Jul 17, 2026 10:00 JST
TANAKA Commences Operation of "TANAKA H2 Nexus", One of Japan's Largest 500 kW Pure Hydrogen Fuel Cell Power Generation Facilities
Jul 16, 2026 22:00 JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Jul 16, 2026 00:18 JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 15, 2026 23:51 JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 15, 2026 23:21 JST
NEC develops world's first proprietary-AI technology to rapidly generate highly detailed 3D models solely from general-purpose camera footage while automatically removing unnecessary subjects
Jul 15, 2026 22:53 JST
Hitachi Rail achieves EcoVadis platinum medal, ranking among the top 1% of companies worldwide for sustainability performance
Jul 15, 2026 22:35 JST
Anime Tokyo Station Reaches 300,000 Visitors!
Jul 15, 2026 11:00 JST
Fujitsu launches AI-driven modernization service to accelerate legacy system transformation
Jul 14, 2026 19:12 JST
Anime Tokyo Station: TV Anime "BLEACH: THE BLOOD WARFARE - The Calamity" Special Exhibition
Jul 14, 2026 11:00 JST
JCB Signs Memorandum of Understanding with Circle to Explore Collaboration Utilizing Stablecoins
Jul 14, 2026 10:00 JST
Mitsubishi Power Receives Contract to Supply Boilers for Fuel Conversion Work at Existing Thermal Power Plants in Saudi Arabia
Jul 14, 2026 00:58 JST
Fujitsu developed an AI Agent to collaborate with store managers for AEON Food Style's strategic store operations
Jul 14, 2026 00:38 JST
More Latest Release >>
Related Release
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
7/18/2026 12:24:00 AM JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
7/16/2026 12:18:00 AM JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
7/15/2026 11:51:00 PM JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
7/15/2026 11:21:00 PM JST
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
7/14/2026 12:06:00 AM JST
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
7/2/2026 10:45:00 PM JST
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
7/2/2026 10:01:00 PM JST
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
6/17/2026 1:28:00 PM JST
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
5/22/2026 12:23:00 AM JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
4/21/2026 8:52:00 PM JST
More Press release >>